Please assess the completion status of the following clinical trial:

Trial Title: Gentamicin Bladder Instillations to Prevent Urinary Tract Infections in Patients With Spinal Cord Injury

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of signed and dated informed consent form and agreement to complete the daily dosing log as instructed by the study coordinator.~* History of traumatic spinal cord injury (SCI) or non-traumatic spinal cord disease, (SCD) with sustained neurological dysfunction~* At least 6 months post-initial hospital discharge following SCI/SCD onset~* Neurogenic bladder~* Ability to perform daily instillation on self or with help of others and willingness to adhere to the study regiment.~* History of at least 2 documented urinary tract infection (UTI) during the previous 6 months (prior to screening)~* Have a designated physician or health care provider for routine care~* Use of clean intermittent catheterization or catheterization through a stoma (i.e. Mitrofanoff) as their primary method of bladder management~Exclusion Criteria:~* Concurrent use of systemic oral or intravesical antibiotic prophylaxis~* Documented or self-reported history of gentamicin allergy~* Female patients who are currently pregnant or attempting to become pregnant~* Patients with a history of 8th cranial nerve disorder~* Co-morbidities like cancer and chronic disease that could impact patient safety OR significantly affect the rate of UTIs and/or quality of life (QOL) substantially~* Urological co-morbidities like bladder cancer and history of kidney disease.~* Current UTI at screening (assessed via urine analysis and culture and symptoms)~* Concurrent enrollment in a similar clinical trial~* Concurrent use of contraindicated diuretics (ethacrynic acid, furosemide)~* Current use of other contraindicated or disallowed concomitant medications or receiving treatments that may influence the results from this study.~* Known allergy to aminoglycoside antibiotics; Otological symptoms at baseline (i.e. tinnitus. severe dizziness/vertigo)~* At the discretion of study team, individuals who are unable or unlikely to comply with procedures and/or for whom study participation is not recommended (e.g. unable to arrange transportation, cognitive and/or behavioral challenges that preclude meaningful participation, poor health, etc.)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Gentamicin sulfate (Type: EXPERIMENTAL): Participants initiate Gentamicin instillations every night for a treatment period of 6 months. Instillations are stopped if they developed a UTI. After receiving treatment for this UTI, they resume the Gentamicin instillations. After baseline screening and being consented, they are instructed on how to do the instillations through a catheter, once they receive the drug and aid equipment (i.e. syringes) to do installations. Remaining drug from syringes are to be disposed after each use. Participants use their own catheters. In-dwelling catheters are not allowed.

Based on this trial design, predict the completion outcome and termination type (if applicable).